9544 Fair Value & Analysis
Healthcare · Market cap 810M SAR
Fair value as of: Jul 31, 2026
From 24 valuation models · updated today
Share price −5.8% over the past month.
What matters now
- The price sits above even our optimistic bull case (0.8400 SAR). The favourable scenario is already priced in.
- Solid but not exceptional quality (56/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (0.4400 SAR to 0.8400 SAR) leaves room in how you read the outcome.
Price vs Fair Value (12 months)
12‑month range 1.51 SAR – 2.90 SAR · fair‑value band 0.4400 SAR – 0.8400 SAR · the 1.62 SAR price screens above the 0.6900 SAR fair value. As of Jul 31, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
9544 (9544) currently trades at 1.62 SAR, while our model-based Fair Value estimate is 0.6900 SAR, implying the stock looks roughly 57.4% overvalued today. We read business quality at 56/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, 9544 generated revenue of 76.1M SAR at a net margin of 20.7%. Revenue grew 45.5% year over year. It earns a return on equity of 17.4%. The balance sheet holds a net cash position of 56.0M SAR. Fundamentals as of Jul 31, 2026
Our scenario range runs from 0.4400 SAR (bear case) to 0.8400 SAR (bull case); at 1.62 SAR, the current price sits above that range. The share trades about 49% below its 52-week high and 8% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -19% fair-value upside, at -57%, 9544 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 31, 2026. TTM = trailing twelve months.
Quality Score breakdown
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
9544 reported revenue of 76.1M SAR in FY2025 versus 72.0M SAR in FY2021, a compound +1.4%/yr. Reported net income was 15.8M SAR in FY2025, compounding −19.1%/yr from FY2021.
Is 9544 fairly valued? → Check now
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 31, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$100.00 | R$25.67 | -74% |
| Fresenius SE FRE | €39.54 | €31.98 | -19% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.76 SGD | 1.28 SGD | -54% |
| Tenet Healthcare Corporation THC | $178.75 | $300.86 | +68% |
| Rede D'Or São Luiz S.A RDOR3 | R$32.50 | R$46.04 | +42% |
| DaVita Inc DVAI34 | R$1,002 | R$1,038 | +4% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,305 | ₹2,546 | -69% |
| Fresenius Medical Care AG FMSC34 | R$112.00 | R$164.60 | +47% |
| Aier Eye Hospital Group 300015 | ¥8.54 | ¥6.73 | -21% |
Compare 9544 with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is 9544 overvalued or undervalued?
What is the fair value of 9544?
What is the quality score of 9544?
What is the revenue of 9544?
What is the net profit margin of 9544?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track 9544 and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.